Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

Detailed price information for Cyclerion Therapeutics Inc (CYCN-Q) from The Globe and Mail including charting and trades.
Daily Excelsior

AI in 2025: From Hype to Habit

Dr. Vishal Sharma [email protected] Not long ago, the word “Artificial Intelligence (AI)” would bring to mind ...

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines ...
eLife

Replication stress-inducing ELF3 upregulation promotes BRCA1-deficient breast tumorigenesis in luminal progenitors

ELF3 axis enables luminal progenitor transformation in BRCA1-deficient breast cancer by reducing genomic instability and promoting progenitor identity.